ABSTRACT
We experimentally demonstrate a simple yet versatile optimal quantum control technique that achieves tailored robustness against qubit inhomogeneities and control errors while requiring minimal bandwidth. We apply the technique to nitrogen-vacancy (NV) centers in diamond and verify its performance using quantum process tomography. In a wide-field NV center magnetometry scenario, we achieve a homogeneous sensitivity across a 33% drop in control amplitude, and we improve the sensitivity by up to 2 orders of magnitude for a normalized detuning as large as 40%, achieving a value of 20 nT Hz(-1/2) µm(3/2) in sensitivity times square root volume.
ABSTRACT
A new method for the straightforward synthesis of 2-amino-[1,2,4]triazolo[1,5-a]pyridines and derivatives is presented. The target products are synthesized in high yields from guanidylpyridines and analogues via copper-catalyzed N-N coupling. The present methodology shows a wide scope, tolerating not only different substituents on the pyridine ring but also different heterocylic rings such as pyrazines, pyrimidines, and pyridazines.
Subject(s)
Copper/chemistry , Guanidine/chemistry , Pyridines/chemistry , Pyrimidines/chemistry , Triazoles/chemical synthesis , Catalysis , Cyclization , Guanidine/analogs & derivatives , Oxidation-Reduction , Triazoles/chemistryABSTRACT
Hyperpolarization-activated and cyclic-nucleotide-gated 1 (HCN1) ion channels are proposed to be critical for cognitive function through regulation of synaptic integration. However, resolving the precise role of HCN1 in neurophysiology and exploiting its therapeutic potential has been hampered by minimally selective antagonists with poor potency and limited in vivo efficiency. Using automated electrophysiology in a small-molecule library screen and chemical optimization, we identified a primary carboxamide series of potent and selective HCN1 inhibitors with a distinct mode of action. In cognition-relevant brain circuits, selective inhibition of native HCN1 produced on-target effects, including enhanced excitatory postsynaptic potential summation, while administration of a selective HCN1 inhibitor to rats recovered decrement working memory. Unlike prior non-selective HCN antagonists, selective HCN1 inhibition did not alter cardiac physiology in human atrial cardiomyocytes or in rats. Collectively, selective HCN1 inhibitors described herein unmask HCN1 as a potential target for the treatment of cognitive dysfunction in brain disorders.
Subject(s)
Memory, Short-Term , Potassium Channels , Rats , Animals , Humans , Potassium Channels/metabolism , Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels/metabolism , Brain/metabolismABSTRACT
Alzheimer's Disease (AD) is the most widespread form of dementia, with one of the pathological hallmarks being the formation of neurofibrillary tangles (NFTs). These tangles consist of phosphorylated Tau fragments. Asparagine endopeptidase (AEP) is a key Tau cleaving enzyme that generates aggregation-prone Tau fragments. Inhibition of AEP to reduce the level of toxic Tau fragment formation could represent a promising therapeutic strategy. Here, we report the first orthosteric, selective, orally bioavailable, and brain penetrant inhibitors with an irreversible binding mode. We outline the development of the series starting from reversible molecules and demonstrate the link between inhibition of AEP and reduction of Tau N368 fragment both in vitro and in vivo.